Skip to content
HowShorted

Verve Therapeutics, Inc. short interest in 2022

In 2022, Verve Therapeutics, Inc.'s disclosed short interest ran from 12.86% of shares outstanding on 14 Jan 2022 to 20.24% on 30 Dec 2022, a change of +7.38 percentage points. The year's high was 20.46% on 15 Jun 2022 and its low 12.86% on 14 Jan 2022, averaging 17.56% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.56 days on 15 Jun 2022. Full history: Verve Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Verve Therapeutics, Inc. in 2022

2022 in figures

Start of year
12.86% (14 Jan 2022)
End of year
20.24% (30 Dec 2022)
Change
+7.38 pp
High
20.46% (15 Jun 2022)
Low
12.86% (14 Jan 2022)
Average
17.56%
Highest days to cover
16.56 (15 Jun 2022)
SEC filings marked
8

Every report in 2022

Verve Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202212.86%12.91
31 Jan 202214.30%7.76
15 Feb 202215.81%15.26
28 Feb 202215.97%12.90
15 Mar 202216.70%13.1010-K filed, results (8-K)
31 Mar 202217.98%8.41
14 Apr 202217.36%14.02
29 Apr 202218.53%15.89
13 May 202219.35%12.4710-Q filed, results (8-K)
31 May 202219.78%16.38
15 Jun 202220.46%16.56
30 Jun 202219.33%8.72
15 Jul 202220.43%10.81
29 Jul 202218.38%4.23
15 Aug 202216.00%9.9010-Q filed, results (8-K)
31 Aug 202216.13%10.37
15 Sep 202216.44%11.52
30 Sep 202220.23%7.92
14 Oct 202217.90%16.39
31 Oct 202216.77%13.80
15 Nov 202216.20%6.4010-Q filed, results (8-K)
30 Nov 202216.42%16.13
15 Dec 202217.79%9.31
30 Dec 202220.24%12.19

See also: Verve Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.